HC Wainwright Has Lowered Expectations for GH Research (NASDAQ:GHRS) Stock Price

GH Research (NASDAQ:GHRS) had its price target decreased by equities researchers at HC Wainwright from $40.00 to $35.00 in a report issued on Monday, Marketbeat reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would indicate a potential upside of 146.13% from the company’s previous close.

Several other analysts also recently commented on GHRS. Zacks Research downgraded GH Research from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Wall Street Zen lowered GH Research from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of GH Research in a research note on Wednesday, October 8th. Finally, Needham & Company LLC started coverage on shares of GH Research in a research report on Monday, October 13th. They issued a “buy” rating and a $19.00 price objective on the stock. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, GH Research currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.75.

GH Research Stock Performance

NASDAQ GHRS opened at $14.22 on Monday. The firm’s fifty day moving average is $13.46 and its two-hundred day moving average is $13.11. GH Research has a one year low of $6.72 and a one year high of $20.50. The firm has a market cap of $739.87 million, a PE ratio of -19.22 and a beta of 0.97.

GH Research (NASDAQ:GHRS) last announced its earnings results on Thursday, November 6th. The company reported ($0.23) earnings per share for the quarter, hitting the consensus estimate of ($0.23). Research analysts predict that GH Research will post -0.8 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Osaic Holdings Inc. raised its position in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after acquiring an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of GH Research during the 2nd quarter worth $79,000. Virtus Investment Advisers LLC purchased a new position in shares of GH Research in the 2nd quarter valued at about $89,000. XTX Topco Ltd purchased a new position in shares of GH Research in the 1st quarter valued at about $169,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of GH Research by 165.4% in the second quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after purchasing an additional 10,600 shares during the period. Institutional investors and hedge funds own 56.90% of the company’s stock.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).